CTOs on the Move

Sanofi Genzyme

www.sanofigenzyme.com

 
Sanofi Genzyme, the specialty care business unit of Sanofi, focuses on rare diseases, multiple sclerosis, oncology, and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. Our approach is shaped by our experience developing highly specialized treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details

Similar Companies

Abner Labs

Abner Innovation Laboratories Limited (“Abner Labs”) is a British Columbia, Canada, company formed to acquire Abner Technology Group Limited (“Abner Group”), owner of the ibetmobile sports viewing and betting technology platform. This proprietary, artificial intelligence (“AI”) driven smart technology makes watching and wagering on live sports on any online device as easy as playing video games.

Crucell Biologics

Crucell N.V. (Crucell) is a biopharmaceutical company. The Company is focused on developing, producing and marketing products that combat infectious diseases. Crucell product candidates include flu-mAb, an antibody product effective against a range of

AbbVie

At AbbVie, we believe the world needs new approaches to addressing today`s health issues — from life-threatening illness to chronic conditions. We combine advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people`s lives. With 28,000+ employees and medicines in over 170 countries, AbbVie is uniting the best of pharma and the boldness of biotech, to innovate end-to-end approaches that make a real difference in people`s lives.

Esperance Pharmaceuticals

Esperance Pharmaceuticals, Inc. is developing a new class of targeted oncology products that selectively kill cancer cells without harming normal cells. Targeting occurs through binding to specific receptors on the cancer cell surface. The novel product candidates destroy dividing and non-dividing cancer cells including those known to be resistant to chemotherapeutics.

Odyssey Behavioral Healthcare

Odyssey Behavioral Health consists of a growing portfolio of quality behavioral health facilities with evidence-based clinical care.